What Is Surfactin Studied For? Research Areas, Per the Literature

Answer in brief

Surfactin is a cyclic lipopeptide biosurfactant produced by Bacillus subtilis and related species. When people ask what surfactin is used for, the honest answer from the published record is that it has been studied mainly in test tubes, on surfaces, in bacterial cultures, in plant disease systems and in cultured human cell lines. Surfactin is not approved by the FDA as a medicine for any condition. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, illness or treatment. For background on the molecule itself, see the surfactin learn hub.

What the molecule is, structurally

Surfactin is not a single compound but a family of closely related isoforms that differ in the length and branching of the fatty acid chain attached to a cyclic heptapeptide. A 2008 analytical study separated and characterised surfactin isoforms produced by Bacillus subtilis HSO121 and reported that the fermentation product was a mixture rather than one uniform species (PMID 18336355). That heterogeneity matters when reading the rest of the literature, because different preparations in different laboratories are not necessarily identical material.

Research area 1: membrane interaction and permeabilization

The most consistently studied property of surfactin is its interaction with lipid membranes. A 2010 biophysical study using model lipid systems reported that surfactin activity depended on the membrane dipole potential, meaning the physical electrostatic properties of the bilayer influenced how the lipopeptide behaved (PMID 20828112). This was an in vitro membrane model experiment, not an animal or human study.

A 2020 in vitro study of bacterial membranes examined why the producing organism is not destroyed by its own product, and researchers reported that cardiolipin in the Bacillus subtilis membrane protected that membrane against surfactin-induced permeabilization (PMID 32593615). Taken together, these two membrane papers describe a mechanism of action at the level of lipid bilayers (PMID 20828112), and they say nothing about safety or efficacy in people.

Research area 2: antibacterial activity and biofilms

Surfactin has been tested against bacteria, with particular attention to surface colonisation. A 2019 in vitro study reported that surfactin inhibited Staphylococcus aureus adhesion and biofilm formation on surfaces (PMID 31011774). The model was bacterial culture on material surfaces, which is relevant to questions about contamination and device fouling rather than to treatment of an infection in a patient.

Related work has looked at lipopeptides from other Bacillus producers. A 2022 study isolated and purified antibacterial lipopeptides from Bacillus velezensis YA215, a strain recovered from sea mangroves, and researchers characterised the antibacterial fractions in laboratory assays (PMID 36505249). These are in vitro microbiology studies in isolated culture systems; neither involved animals or human participants.

Why surface and biofilm work is not the same as an antibiotic claim

In vitro inhibition of adhesion on a surface (PMID 31011774) describes what happened in a controlled culture system. It does not establish absorption, distribution, tolerability or clinical benefit, and the verified literature summarised here contains no human trial of surfactin as an anti-infective.

Research area 3: resistant organisms and nanoparticle formulations

One line of work has combined surfactin with nanomaterials. A 2019 study reported that bio-surfactin stabilised silver nanoparticles exerted an inhibitory effect against New Delhi metallo-beta-lactamases and against cells harbouring those enzymes (PMID 31150546). The study was performed in enzyme and bacterial cell systems in vitro, and the active entity tested was a nanoparticle formulation in which surfactin acted as a stabiliser, not surfactin alone.

Research area 4: agricultural biocontrol of plant pathogens

A substantial share of lipopeptide research sits in plant pathology rather than medicine. A 2026 study in The ISME Journal examined metabolite interactions between Bacillus and Trichoderma and reported that those interactions mediated beneficial alliances that contributed to control of Fusarium wilt (PMID 41454779). The models were microbial communities and plant disease systems, not mammals.

A 2022 plant disease study tested Bacillus amyloliquefaciens SDTB009 together with the fungicide difenoconazole and reported synergistic effects against Fusarium wilt of tomato (PMID 35077231). That study evaluated a surfactin-producing genus in a crop protection setting, so it is best read as agricultural microbiology rather than as evidence about purified surfactin in humans.

Research area 5: cancer cell line experiments

Searches for surfactin uses often surface oncology language, and there is a preclinical basis for that interest, but it is cell culture only. A 2013 in vitro study using HepG2 human liver cancer cells reported that surfactin induced apoptosis through ROS, endoplasmic reticulum stress, calcium and ERK pathways (PMID 23733672). The model was an immortalised cell line in a dish. No animal efficacy study or human oncology trial of surfactin appears in the verified set summarised here, and cell line apoptosis findings (PMID 23733672) have historically translated poorly without further stages of testing.

Research area 6: microbial ecology and gene transfer

Surfactin also has a role in the biology of the organism that makes it. A 2021 microbiology study reported that surfactin facilitated horizontal gene transfer in Bacillus subtilis (PMID 34054753). That work was conducted in bacterial culture and is of interest to microbial genetics and biotechnology, including questions about how genetic material moves between bacteria.

Research area 7: chemistry, stability and mineral interfaces

Several papers treat surfactin as an industrial surfactant rather than a bioactive. A 2019 chemistry study examined hydrolysis of surfactin over activated carbon and characterised the resulting conversion of the molecule (PMID 30952450). A separate 2019 colloid study reported that a lipopeptide biosurfactant influenced the precipitation of calcium carbonate (PMID 30448711), which is relevant to scale formation, biomineralisation and materials processing. Both were bench chemistry experiments with no biological model.

Summary table of study types

Safety and Tolerability: What Studies Report

The verified papers summarised on this page did not include human safety trials, animal toxicology studies or adverse event reporting in people. What they described instead is a mechanism that is inherently disruptive to lipid membranes: researchers reported that surfactin permeabilised membranes in a manner dependent on membrane properties (PMID 20828112), and a separate study reported that cardiolipin content altered susceptibility of a bacterial membrane to that permeabilization (PMID 32593615). A cell line study reported cell death signalling in human hepatoma cells exposed to surfactin (PMID 23733672), which indicates cytotoxic potential in culture rather than a demonstrated therapeutic margin. Because no human tolerability data appear in this set, no statement about human safety can be supported from it.

Where the evidence is weak or absent

• Human clinical use: no human trials of surfactin appear in the verified literature summarised here; the membrane, antibacterial and cell line findings are all preclinical (PMID 31011774).
• Oncology: evidence is limited to a single cultured cell line experiment describing apoptosis pathways (PMID 23733672), with no animal or human outcome data in this set.
• Antimicrobial therapy: the available work is surface, enzyme and culture based (PMID 31150546), not infection treatment in a living host.
• Immune, metabolic or anti-inflammatory uses: the verified set contains no study addressing those endpoints, so nothing here supports such claims.
• Product consistency: because commercial and research surfactin is an isoform mixture (PMID 18336355), results from one preparation do not automatically generalise to another.

How to read surfactin claims critically

1. Identify the model. Membrane vesicles, bacterial cultures, tomato plants and HepG2 cells are different worlds, and the study of apoptosis signalling was conducted in cells only (PMID 23733672).
2. Check whether the tested material was surfactin itself or a formulation, since one study tested silver nanoparticles stabilised by surfactin (PMID 31150546).
3. Separate agricultural outcomes from medical ones, because crop disease studies measured plant disease control (PMID 35077231).
4. Notice when a genus rather than a purified molecule was studied, as in the microbial alliance work (PMID 41454779).

Bottom line

Across the verified literature, surfactin has been studied as a membrane active biosurfactant (PMID 20828112), as an antibiofilm and antibacterial agent in culture (PMID 31011774), as a factor in bacterial gene transfer (PMID 34054753), as part of agricultural biocontrol systems (PMID 41454779), and as an industrial surfactant in chemistry experiments (PMID 30448711). Surfactin is not approved by the FDA as a medicine for any condition. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician for questions about health or treatment.

References

• Surfactin isoforms from Bacillus subtilis HSO121: separation and characterization (Protein and Peptide Letters, 2008)
• Surfactin activity depends on the membrane dipole potential (Langmuir, 2010)
• Surfactin-induced apoptosis through ROS-ERS-Ca2+-ERK pathways in HepG2 cells (Cell Biochemistry and Biophysics, 2013)
• Effect of a lipopeptide biosurfactant on the precipitation of calcium carbonate (Colloids and Surfaces B: Biointerfaces, 2019)
• Hydrolysis of surfactin over activated carbon (Bioorganic Chemistry, 2019)
• Surfactin effectively inhibits Staphylococcus aureus adhesion and biofilm formation on surfaces (Applied Microbiology and Biotechnology, 2019)
• Bio-surfactin stabilised silver nanoparticles exert inhibitory effect over New-Delhi metallo-beta-lactamases (NDMs) and the cells harbouring NDMs (FEMS Microbiology Letters, 2019)
• Bacillus subtilis cardiolipin protects its own membrane against surfactin-induced permeabilization (Biochimica et Biophysica Acta Biomembranes, 2020)
• Surfactin Facilitates Horizontal Gene Transfer in Bacillus subtilis (Frontiers in Microbiology, 2021)
• Synergistic Effects of Bacillus amyloliquefaciens SDTB009 and Difenoconazole on Fusarium Wilt of Tomato (Plant Disease, 2022)
• Isolation and purification of antibacterial lipopeptides from Bacillus velezensis YA215 isolated from sea mangroves (Frontiers in Nutrition, 2022)
• Metabolite interactions mediate beneficial alliances between Bacillus and Trichoderma for effective Fusarium wilt control (The ISME Journal, 2026)